Ignite Creation Date:
2024-05-06 @ 7:09 AM
Last Modification Date:
2024-10-26 @ 11:45 AM
Study NCT ID:
NCT02476019
Status:
COMPLETED
Last Update Posted:
2018-06-25
First Post:
2015-06-15
Brief Title:
A Safety Tolerability PK and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients
Sponsor:
Ionis Pharmaceuticals Inc
Organization:
Ionis Pharmaceuticals Inc
Study Overview
Official Title:
A Double Blind Randomized Placebo-controlled Single Center Phase 2a Study to Determine the Safety Tolerability Pharmacokinetics and Pharmacodynamics of ISIS 463588 ISIS-FGFR4RX an Antisense Inhibitor of Fibroblast Growth Factor Receptor 4 Administered Subcutaneously Once Weekly for 13 Weeks in Obese Patients
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FGFR4-CS2
Brief Summary:
The purpose of this study is to to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of ISIS-FGFR4RX
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None